TScan Therapeutics Inc
TCRX1.115USD
-0.020-1.76%
交易中 （美东）报价延迟15分钟
63.27M总市值
亏损市盈率 TTM
关于 TScan Therapeutics Inc 公司
TScan Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发一系列 T 细胞受体工程 T 细胞 (TCR-T) 疗法，用于治疗癌症患者。该公司的主要 TCR-T 疗法候选药物 TSC-100 和 TSC-101 正在进行临床开发，用于治疗血液系统恶性肿瘤患者，以消除残留疾病并防止异基因造血细胞移植后的复发。该公司还在开发多路复用 TCR-T 疗法候选药物，用于治疗各种实体瘤。该公司已经开发并继续建立其 ImmunoBank，这是 TCR 领域不同人类白细胞抗原 (HLA) 类型的实体瘤靶标集合。该公司正在推进大约六个实体瘤项目：TSC-204、TSC-200、TSC-203、TSC-201、TSC-202 和 TSC-205。
TScan Therapeutics Inc简介
公司代码TCRX
公司名称TScan Therapeutics Inc
上市日期Jul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
员工数量194
证券类型Ordinary Share
年结日Jul 16
公司地址830 Winter Street
城市WALTHAM
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02451
电话18573999500
网址https://www.tscan.com
公司代码TCRX
上市日期Jul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
TScan Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
暂无数据
地区USD
名称
营收
占比
United States
3.08M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 10月2日 周四
更新时间: 10月2日 周四
持股股东
股东类型
持股股东
持股股东
占比
Lynx1 Capital Advisors LLC
14.97%
BVF Partners L.P.
9.96%
K2 HealthVentures LLC
6.87%
Baker Bros. Advisors LP
5.31%
The Vanguard Group, Inc.
4.10%
其他
58.80%
持股股东
持股股东
占比
Lynx1 Capital Advisors LLC
14.97%
BVF Partners L.P.
9.96%
K2 HealthVentures LLC
6.87%
Baker Bros. Advisors LP
5.31%
The Vanguard Group, Inc.
4.10%
其他
58.80%
股东类型
持股股东
占比
Investment Advisor
27.15%
Hedge Fund
21.45%
Venture Capital
15.27%
Investment Advisor/Hedge Fund
7.33%
Research Firm
3.61%
Individual Investor
0.39%
Bank and Trust
0.27%
其他
24.53%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
198
41.48M
79.05%
-8.70M
2025Q2
192
48.33M
92.38%
-952.90K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Lynx1 Capital Advisors LLC
7.86M
14.97%
-88.79K
-1.12%
Jun 30, 2025
BVF Partners L.P.
5.23M
9.96%
+336.60K
+6.88%
Jun 30, 2025
K2 HealthVentures LLC
3.60M
6.87%
+2.90M
+414.67%
Dec 31, 2024
Baker Bros. Advisors LP
2.78M
5.31%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.15M
4.1%
-207.37K
-8.80%
Jun 30, 2025
Propel Bio Management, LLC
2.09M
3.98%
--
--
Jun 30, 2025
BlackRock Financial Management, Inc.
1.32M
2.51%
-529.55K
-28.71%
Jun 30, 2025
Bessemer Venture Partners
1.25M
2.37%
--
--
Jun 30, 2025
Alphabet, Inc.
1.08M
2.05%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
915.95K
1.75%
-1.69M
-64.89%
Jun 30, 2025
查看更多
持股ETF
更新时间: 3 小时前
更新时间: 3 小时前
机构名称
占比
Simplify Propel Opportunities ETF
2.49%
iShares Health Innovation Active ETF
0.1%
iShares Micro-Cap ETF
0.02%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 3000 ETF
0%
查看更多
Simplify Propel Opportunities ETF
占比2.49%
iShares Health Innovation Active ETF
占比0.1%
iShares Micro-Cap ETF
占比0.02%
iShares Biotechnology ETF
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0.01%
ProShares Ultra Nasdaq Biotechnology
占比0.01%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
iShares Russell 3000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
